will be hosted with bootnetworks.com
If you have any questions email
or visit www.bootnetworks.com
If you have a web hosting account and need information on uploading your web site, CLICK HERE.
lajollabiotech.com
Having trouble? Log on to support.bootnetworks.com with your username and password, or email
lajollabiotech
Cambridge Team First to Grow Smooth Muscle Cells from Patient Skin Cells
A Cambridge University research team has for the first time discovered a method of generating different types of vascular smooth muscle cells (SMCs) - the cells which make up the walls of blood vessels - using cells from patients' skin. This work could lead to new treatments and better screening for...
Heptares scientists report the first use of structure-based drug design to discover GPCR-targeted drug candidate
Heptares Therapeutics provided an update on recent scientific publications that highlight its unique ability to generate valuable information on GPCR structures and ligand binding.
In the first of two new papers published in Journal of Medicinal Chemistry, Heptares scientists describe how completely...
Heptares granted patents covering stabilised receptor technology in Europe and Japan
Heptares Therapeutics announced that the first of a series of patent applications covering its methods for generating G-protein coupled receptors (GPCR) with increased conformational stability (StaR® technology) has resulted in patents being granted in Europe (EP2121919) and Japan (JP4842400). This...
Affectis Granted Patent for AFC-5128, other P2X7 Antagonists
Affectis Pharmaceuticals AG announced that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 which is being developed for the treatment of neuropathic pain and multiple sclerosis.The European patent EP2105164 is related to the composition of AF...
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
MediGene AG continues clinical development of its drug candidate RhuDex® by initiating a clinical formulation study. The trial objective is to develop an optimized oral formulation of the active substance suitable for the treatment of chronic diseases. The results of this formulation study are expec...
Powered by Boot Networks Web Hosting